Edmund Lacour, MD
Rheumatology · Dothan, ALNPI 1285689463
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 447 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by Amgen at 27.1% of the total. That places this record below the midpoint for rheumatology clinicians in AL, where the typical reported total is $8,965.
Across 447 payments — averaging $21.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AbbVie$2K
- Johnson & Johnson$715
- Novartis$618
- Aurinia Pharma U.S., Inc.$507
- Janssen Scientific Affairs, LLC$351
- plus $3K from 31 others
Across 280 payments — averaging $1138.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sun Pharmaceutical Industries Inc.$318K
- Novartis$1K
What the payments were for
- Food & beverage$9,10196%
- Education$3043%
- Other$521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 143 | $2,560 |
| AbbVie | 130 | $2,005 |
| Johnson & Johnson(2 entities) | 34 | $715 |
| Novartis | 13 | $618 |
| Aurinia Pharma U.S., Inc. | 14 | $507 |
| Janssen Scientific Affairs, LLC | 4 | $351 |
| UCB, Inc. | 13 | $282 |
| Boehringer Ingelheim | 11 | $279 |
| Radius Health, Inc. | 7 | $266 |
| AstraZeneca | 3 | $257 |
| E.r. Squibb & Sons, L.L.C. | 11 | $248 |
| Lilly USA, LLC | 7 | $228 |
| Genentech USA, Inc. | 16 | $208 |
| Pfizer | 5 | $189 |
| GSK | 2 | $108 |
| ANI Pharmaceuticals, Inc. | 4 | $95 |
| Medtronic(2 entities) | 3 | $78 |
| Mallinckrodt Hospital Products Inc. | 3 | $61 |
| Corcept Therapeutics | 4 | $51 |
| Sanofi | 1 | $34 |
| Amarin Pharma, Inc. | 2 | $28 |
| Welch Allyn | 1 | $26 |
| Baxter Healthcare | 1 | $26 |
| Novo Nordisk | 2 | $24 |
| Smith+Nephew | 1 | $22 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Bioventus LLC | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,457 in reported general payments places this provider in the 50th percentile of 90 rheumatology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 225 | $2,070,157 |
| Enbrel SureclickEtanercept | 201 | $1,562,056 |
| RinvoqUpadacitinib | 222 | $1,470,273 |
| StelaraUstekinumab | 54 | $1,050,948 |
| Skyrizi PenRisankizumab-Rzaa | 27 | $553,123 |
| TremfyaGuselkumab | 40 | $526,838 |
| Orencia ClickjectAbatacept | 90 | $511,058 |
| Taltz AutoinjectorIxekizumab | 68 | $475,251 |
| ProliaDenosumab | 268 | $462,308 |
| Xeljanz XrTofacitinib Citrate | 81 | $455,354 |
| Cimzia (2 Pack)Certolizumab Pegol | 54 | $324,375 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 23 | $259,387 |
| Actemra ActpenTocilizumab | 60 | $241,668 |
| OrenciaAbatacept/Maltose | 44 | $208,254 |
| Humira PenAdalimumab | 14 | $176,166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara, Tremfya, Simponi, Simponi Aria | $715 | $1,881,799133 claims |
| AbbVieRinvoq, Humira | $2,005 | $1,540,182233 claims |
| AmgenProlia, Enbrel, Otezla | $2,560 | $638,967297 claims |
| UCB, Inc.Cimzia (2 Pack) | $282 | $324,37554 claims |
| PfizerOctagam, Xeljanz | $189 | $243,86845 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $248 | $208,25444 claims |
| GSKBenlysta | $108 | $150,87642 claims |
| Lilly USA, LLCOlumiant | $228 | $62,10923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 90 rheumatology providers in Alabama.
Other rheumatology in Dothan
- Anthony TurkiewiczMountain Brk$2.2M
- Jeffrey CurtisBirmingham$612K
- David McLainBirmingham$588K
- Ray McLaughinTuscaloosa$332K
- Elizabeth PerkinsHoover$264K
- Peter SawayMountain Brk$166K
- Kenneth SaagBirmingham$143K
- Gino DivittorioMobile$139K
- Richard JonesNorthport$126K
- William ShergyHuntsville$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.